JP2025512920A5 - - Google Patents

Info

Publication number
JP2025512920A5
JP2025512920A5 JP2024558345A JP2024558345A JP2025512920A5 JP 2025512920 A5 JP2025512920 A5 JP 2025512920A5 JP 2024558345 A JP2024558345 A JP 2024558345A JP 2024558345 A JP2024558345 A JP 2024558345A JP 2025512920 A5 JP2025512920 A5 JP 2025512920A5
Authority
JP
Japan
Prior art keywords
approximately
solid form
xrpd pattern
form according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065434 external-priority patent/WO2023196900A1/en
Publication of JP2025512920A publication Critical patent/JP2025512920A/ja
Publication of JP2025512920A5 publication Critical patent/JP2025512920A5/ja
Pending legal-status Critical Current

Links

JP2024558345A 2022-04-07 2023-04-06 ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製 Pending JP2025512920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328609P 2022-04-07 2022-04-07
US63/328,609 2022-04-07
PCT/US2023/065434 WO2023196900A1 (en) 2022-04-07 2023-04-06 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Publications (2)

Publication Number Publication Date
JP2025512920A JP2025512920A (ja) 2025-04-22
JP2025512920A5 true JP2025512920A5 (https=) 2026-04-15

Family

ID=86271875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024558345A Pending JP2025512920A (ja) 2022-04-07 2023-04-06 ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製

Country Status (11)

Country Link
US (1) US20230322797A1 (https=)
EP (1) EP4504736A1 (https=)
JP (1) JP2025512920A (https=)
KR (1) KR20250008742A (https=)
CN (1) CN119072481A (https=)
AU (1) AU2023249641A1 (https=)
CA (1) CA3245701A1 (https=)
IL (1) IL315520A (https=)
MX (1) MX2024011951A (https=)
TW (1) TW202400608A (https=)
WO (1) WO2023196900A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
WO2026026817A1 (zh) * 2024-07-29 2026-02-05 海南先声再明医药股份有限公司 大环类alk抑制剂、其制备方法和用途
CN119264053A (zh) * 2024-09-29 2025-01-07 上海凌凯科技股份有限公司 一类吡唑衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP4146205A4 (en) * 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS

Similar Documents

Publication Publication Date Title
JP2025512920A5 (https=)
US11780834B2 (en) Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
JP2024537795A5 (https=)
EP3428159A1 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
JP5378241B2 (ja) 治療化合物
JP2021529805A5 (https=)
WO2009075504A2 (en) Crystalline form of bepotastine p-toluenesulfonate, method for preparing same and pharmaceutical composition containing same
TWI827152B (zh) 式i化合物的晶型及其製備和應用
JP2024526952A5 (https=)
US8410113B2 (en) (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof
JP2023523165A5 (https=)
CN119968370A (zh) 用于制备1-(8-溴吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基氮杂环丁烷-3-胺的盐和结晶形式的方法和新结晶形式
JP2024505967A5 (https=)
WO2014063752A1 (en) Process for making crystalline form alpha of eletriptan hydrobromide
HK1107346A (en) Process for the preparation of 2-methyl piperazine derivatives